Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review

Intranasal form of esketamine, the S-enantiomer of racemic ketamine, was approved by the US FDA in 2019 for treatment-resistant depression (TRD) in adults. Since intranasal esketamine is a newly approved drug with a novel mechanism of action, much still remains unknown in regard to its use in TRD. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Sapkota, Alisha, Khurshid, Hajra, Qureshi, Israa A, Jahan, Nasrin, Went, Terry R, Sultan, Waleed, Alfonso, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Psychiatry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381465/
https://www.ncbi.nlm.nih.gov/pubmed/34447651
http://dx.doi.org/10.7759/cureus.17352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381465/
https://www.ncbi.nlm.nih.gov/pubmed/34447651
http://dx.doi.org/10.7759/cureus.17352

Ejemplares similares